FDA Accepts Supplemental NDA for YONSA by Sun Pharma
The FDA has accepted a supplemental NDA for YONSA, which contains abiraterone acetate as the active ingredient.
Asset / Drug
Drug and asset intelligence for YONSA with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Hormonal Therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.